Necrotizing Enterocolitis clinical trials at UCSF
1 research study open to eligible people
Showing trials for
Feasibility Study to Evaluate Safety and Probable Benefit of the Eclipse XL1 System for Distraction Enterogenesis in Adult and Pediatric Patients With Short Bowel Syndrome
open to eligible people ages 3 months to 65 years
A Feasibility Study to Evaluate Safety and Probable Benefit of the Eclipse XL1 System for Distraction Enterogenesis in Adult and Pediatric Patients with Short Bowel Syndrome
San Francisco 5391959, California 5332921 and other locations
Our lead scientists for Necrotizing Enterocolitis research studies include Matthew Lin, MD.
Last updated: